{
    "data": [
        {
            "id": "4393015",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-04T10:57:45-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Despite Strong Fundamentals, Eli Lilly Is In Short-Term Downward Trend",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20715",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "303582",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4393015-despite-strong-fundamentals-eli-lilly-is-in-short-term-downward-trend"
            }
        },
        {
            "id": "4381321",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-26T10:48:47-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Pauses COVID-19 Study; Latest Acquisition Provides Potential To Target Large Markets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "298039",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4381321-eli-lilly-pauses-covidminus-19-study-latest-acquisition-provides-potential-to-target-large"
            }
        },
        {
            "id": "4375634",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-22T03:44:01-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Reports MonarchE Data, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293388",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4375634-eli-lilly-reports-monarche-data-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4372534",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-03T22:30:47-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Jardiance Data, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "291107",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4372534-eli-lilly-jardiance-data-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4371155",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-27T14:09:33-04:00",
                "isLockedPro": false,
                "commentCount": 125,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID-19 Treatments: Remdesivir Disappoints, Antiviral SPL7013 And Monoclonal Antibodies Interesting For Prevention/Early-Stage Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290110",
                            "type": "sentiment"
                        },
                        {
                            "id": "290111",
                            "type": "sentiment"
                        },
                        {
                            "id": "290112",
                            "type": "sentiment"
                        },
                        {
                            "id": "290113",
                            "type": "sentiment"
                        },
                        {
                            "id": "290075",
                            "type": "sentiment"
                        },
                        {
                            "id": "290076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4371155-covidminus-19-treatments-remdesivir-disappoints-antiviral-spl7013-and-monoclonal-antibodies"
            }
        },
        {
            "id": "4358678",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-15T15:47:27-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Upside Momentum Fading Fast",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "284132",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4358678-eli-lilly-upside-momentum-fading-fast"
            }
        },
        {
            "id": "4354998",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-22T12:16:35-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "IPO Update: Akouos Readies Plan For $125 Million U.S. IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "280971",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4354998-ipo-update-akouos-readies-plan-for-125-million-u-s-ipo"
            }
        },
        {
            "id": "4353562",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-12T13:49:27-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Akouos Aims For U.S. IPO Effort",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "279688",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4353562-akouos-aims-for-u-s-ipo-effort"
            }
        },
        {
            "id": "4353164",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-10T16:32:51-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I Like Eli Lilly, But I Like It Better At The $130 Level",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20715",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "279357",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4353164-i-like-eli-lilly-i-like-better-130-level"
            }
        },
        {
            "id": "4347686",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-14T16:01:58-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Upward Growth Trend Can Continue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "275381",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4347686-eli-lilly-upward-growth-trend-can-continue"
            }
        },
        {
            "id": "4346063",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-11T10:48:20-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Retevmo, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274882",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4346063-eli-lillys-retevmo-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4320634",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-31T13:43:07-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Wait For A Lower Entry Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "259014",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4320634-eli-lilly-wait-for-lower-entry-price"
            }
        },
        {
            "id": "4318229",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-22T04:25:17-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "256460",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4318229-eli-lillys-acquisition-strategy-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4316405",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-13T00:03:25-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: More M&A To Add To The Pipeline Momentum",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "254058",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4316405-eli-lilly-m-to-add-to-pipeline-momentum"
            }
        }
    ]
}